Atopic Dermatitis
Conditions
Interventions
Sponsors
Second Affiliated Hospital ZheJiang University College of Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Adults of both sexes, age between 18an 60 years with actual AD; (2) Patients with a objective SCORAD value between 10 and 40; (3) According to histamine equivalent, the result of the skin prick test kit for Dermatophagoides Farinae should be positive, ++ or above; (4) Patients are able to understand and sign the informed consent form, and should get it before all the assessments; (5) The pregnancy texts of child-bearing period patients should be negetive, reliably contraception during the trial; (6) Compliant this clinical research plan.
Exclusion criteria
Exclusion criteria: (1) Patients who are allergic to non-dust-mite allergens, including wormwood pollen, plane tree pollen, the German cockroach, cat's fur/cat's epithelium, dog's fur/ dog's epithelium, Penicillium, milk, peanuts, Egg yellow, Egg white and at the same time, in the pricking test, the positive results of the above allergens must be stronger than dust-mite allergen with +++ or more; (2) Women in conception and lactation period or have conception project in one year; (3) Patients who had dermalosis may disturb the result assessment; (4) Patients treated with antihistamine or exteral drug in the 1 weeks before the start of the study; (5) Patients treated systemically with corticosteroids or immunosuppressant agents or leukotriene antagonist in the 4 weeks before the start of the study; (6) Patients treated with UV radiation in the 4 weeks before the start of the study; (7) Patients who had immunosuppressive diseases(example:malignant tumor of history of it, history of HIV), autoimmune diseases or history of pulmonary tuberculosis; (8) Patients subsequently severe liver disease(ALT and(or) 1.5 times above the upper limit of normal value), decreased renal function(serum creatinine above the upper limit of normal value) or any other severe diseases; (9) Patients with allergic bronchial asthma requiring systemic steroids and/or ß-receptor agonists(including injection, oral and inhalation); (10) Patients with beta-receptor blockers; (11) Patients who had a history of drup trials within the last 3 months; (12) Patients who had a history of immunotherapy with HDM with the last 3 years; (13) Patients with severe nental disorders; (14) Any other unsuited affairs to participate in clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| indication medication scores;the changes in SCORAD versus baseline: including its decline value and decline percentage; | — |
Secondary
| Measure | Time frame |
|---|---|
| DLQI;the changes of skin lesions scope, and the rescue percentage of each clinical symptom;the changes of the level of itching and its effect on sleep; | — |
Countries
China
Contacts
Public ContactZhang Lu
Outcome results
None listed